EyeWorld Asia-Pacific June 2012 Issue

June 2012 24 EWAP CATARACT/IOL ciliary muscle relaxes and pulls peripherally on the zonular fibers, it is squeezing the capsule so that the lens is squeezed together and that front optic moves back.” One of the things that Dr. Packer sees as setting the dual-optic lens apart is the fact that it keeps the capsule open and allows circulation of aqueous there. He pointed out that other lenses like the FluidVision have an open capsule but are too thick to allow free aqueous circulation. “But this has a design where there are channels around the front of the optic that allow aqueous to circulate into the capsule so that it is kept open,” he said. “As a result of that, these capsules stay remarkably clear—there is virtually no capsular opacification.” During the study no touchup procedures were allowed and due to the larger incision needed here, more astigmatism was induced. Even so, Dr. Packer found that approximately 80% of patients were free of glasses. Currently the Synchrony lens is CE marked. FDA studies were completed in the U.S., where it is awaiting approval. Tightly titrated characteristics With the Tetraflex lens (Lenstec, St. Petersburg, Fla., USA), the theory is that accommodation results from an increase in higher-order aberrations, according to Paul J. Dougherty, MD , clinical instructor of ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, Calif., USA, and medical director, Dougherty Laser Vision, Los Angeles. “The way we think it works is that during the accommodative effort, ciliary muscle contraction and/ Getting - from page 21 or increased vitreous pressure deforms the lens and causes higher-order aberrations, which are one of the natural mechanisms of accommodation,” Dr. Dougherty said. “There may be some small effect of movement of the lens, but we know that doesn’t account for all the effect of the lens.” When investigators looked at SUPRACOR is CE marked. SUPRACOR for myopic, emmetropic, and post-LASIK patients is currently in clinical evaluation. SUPRACOR is NOT approved for use in the US. Technolas Excimer 217P is NOT approved for use in the US. Some of the products and/or specific features as well as the procedures featured in this document may not be approved in your country and thus may not be available there. Design and specifications are subject to change without prior notice as a result of ongoing technical development. Please contact our regional representative regarding individual availability in your respective market. The trademarks (™ and ®) and logos used in this document are the property ofTechnolas PerfectVision GmbH or the respective owner. Design by kbcomunicacion. Ref.TPV-044/06-2012 ©2012Technolas PerfectVision GmbH. All rights reserved. Varifocal excimer treatment for presbyopia Excellent far, intermediate, and near vision* Treats a wide range of patients As simple as a LASIK procedure Expanding LASIK to the presbyopia market Technolas Perfect Vision GmbH Messerschmittstr. 1 + 3, 80992 München, Germany Regional Office Asia-Pacific Technolas Singapore Pte Ltd 101 Thomson Road, #27-03A United Square Singapore 307591 Tel: +65-6592-0792 www.technolaspv.com